Prevention

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

A new study in The Lancet maps trends in vaccine confidence around the world.

New guidance from the Infectious Diseases Society of America offers timely practice advice for the clinical treatment of three of the most common drug-resistant pathogens.

Evidence is accumulating that influenza vaccination protection wanes over the course of a single influenza season, with significant implications for public health.

Robert H. Christenson, PhD, describes the threat of AMR and the role of relevant diagnostics in clinical settings.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

The challenges of making formulary and clinical decisions based on regulatory studies are significant and the need for real-world clinical experience is increasingly important.

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Dr. Pol Vandenbroucke describes the individual and collective risks associated with rising antibiotic resistance.

Dr. Pol Vandenbroucke talks about what makes antibiotic stewardship so important to clinicians and researchers.

Dr. Pol Vandenbroucke explains how the development of health and civil society infrastructure around the world helps to slow antimicrobial resistance.

Dr. Pol Vandenbroucke describes the alarming global threat of antimicrobial resistance.

Providing oral antibiotics to people who inject drugs with infections may reduce hospital readmissions.

Expansion of antimicrobial stewardship strategies to include vertical methods represents an opportunity for programs, both new and established, to further optimize antimicrobial use.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.